What's Next For Artificial Intelligence In The Clinic?
Numerate CEO Guido Lanza talks to Scrip about how artificial Intelligence, or AI, has been quietly used by some drug developers for the last decade, but its use is now rocketing. Also, what is next for AI in pharma?
You may also be interested in...
Artificial intelligence companies focused on the life science sector have boomed in the past decade. Many of these firms are working with pharma partners and a small number are pursuing their own drug development pipelines.
AstraZeneca is the most recent big pharma to team up with an artificial intelligence business – following in the footsteps of Takeda, Johnson & Johnson, Sanofi and GlaxoSmithKline – having signed a drug discovery deal with Boston-based BERG.
Catherine Owen joined Bristol Myers Squibb in September 2019, tasked with overseeing the integration of Celgene and BMS’s international businesses. She talks to In Vivo about managing the merger of teams from two very distinct companies during a global pandemic. Owen, who is passionate about career growth and mentoring, also highlights the importance of talent development and sponsorship – even in times of uncertainty, when business as usual goes out the window.